Comparative efficacy and safety of dual-combination vs. triple-combination antihypertensive therapies in hypertensive patients: an updated meta-analysis of randomized controlled trials. [PDF]
Gong Z, Huang L, Long X, Zhang Y.
europepmc +1 more source
This systematic review synthesizes prognostic models for survival and recurrence in resected non‐small cell lung cancer. While many models demonstrate moderate to good discrimination, few are externally validated and reporting quality is variable, limiting clinical applicability and highlighting the need for robust, transparent model development ...
Evangeline Samuel +4 more
wiley +1 more source
Phage-quinolone synergy: mechanisms, clinical strategies, and translational prospects. [PDF]
Li X, Yao S, Huang G.
europepmc +1 more source
ABSTRACT Objective Super‐Refractory Status Epilepticus (SRSE) is a rare, life‐threatening neurological emergency with unclear etiology in many cases. Mitochondrial dysfunction, often due to disease‐causing genetic variants, is increasingly recognized as a cause, with each gene producing distinct pathophysiological mechanisms.
Pouria Mohammadi +2 more
wiley +1 more source
Effect of the initial combination approach vs initial monotherapy approach on 1-year trajectories of adherence in drug-naive patients with type 2 diabetes. [PDF]
Fatima B +3 more
europepmc +1 more source
ABSTRACT Background SOX1 antibody‐positive paraneoplastic neurological syndromes (PNS) exhibit significant population‐specific clinical heterogeneity. While Western cohorts predominantly manifest Lambert‐Eaton myasthenic syndrome (65%–80%), comprehensive clinical characterization and treatment response data in Asian populations remain critically ...
Jin‐Long Ye +11 more
wiley +1 more source
Editorial: Innovative drug combinations for enhanced solid tumor treatment efficacy
Giovanna Damia, Massimo Broggini
doaj +1 more source
Clustering Algorithm Reveals Dopamine‐Motor Mismatch in Cognitively Preserved Parkinson's Disease
ABSTRACT Objective To explore the relationship between dopaminergic denervation and motor impairment in two de novo Parkinson's disease (PD) cohorts. Methods n = 249 PD patients from Parkinson's Progression Markers Initiative (PPMI) and n = 84 from an external clinical cohort.
Rachele Malito +14 more
wiley +1 more source
First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignancies. [PDF]
Naing A +15 more
europepmc +1 more source

